Page last updated: 2024-10-16

adenine and Nasal Bleeding

adenine has been researched along with Nasal Bleeding in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Ibrutinib combined with rituximab is active and well tolerated in patients with relapsed or refractory mantle cell lymphoma."2.82Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. ( Addison, A; Badillo, M; Champlin, R; Chen, W; Chuang, H; DeLa Rosa, M; Fayad, L; Hagemeister, F; Lam, L; Lee, H; Li, S; Medeiros, LJ; Nomie, K; Oki, Y; Romaguera, J; Samaniego, F; Santos, D; Turturro, F; Wagner-Bartak, N; Wang, ML; Westin, J; Young, KH; Zhang, H; Zhang, L; Zhao, D, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wang, ML1
Lee, H1
Chuang, H1
Wagner-Bartak, N1
Hagemeister, F1
Westin, J1
Fayad, L1
Samaniego, F1
Turturro, F1
Oki, Y1
Chen, W1
Badillo, M1
Nomie, K1
DeLa Rosa, M1
Zhao, D1
Lam, L1
Addison, A1
Zhang, H1
Young, KH1
Li, S1
Santos, D1
Medeiros, LJ1
Champlin, R1
Romaguera, J1
Zhang, L1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL[NCT01880567]Phase 2113 participants (Actual)Interventional2013-07-15Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for adenine and Nasal Bleeding

ArticleYear
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillatio

2016